Filing Flows › 8-K events › ImmunityBio
ImmunityBio: regulation fd disclosure
Form 8-K filed Nov 9, 2026 · items 7.01
FDA decisionsImmunityBio Announces ANKTIVA ® Plus BCG Meets Primary Endpoint in
What the filing says
ImmunityBio Announces ANKTIVA ® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
Read the filing on SEC EDGAR →
ImmunityBio at a glance
Latest quarterQ3 2026
Revenue$48.8M
Revenue Y/Y+52%
Operating margin-159.7%
IndustryBiological Products, (No Diagnostic Substances)
ImmunityBio, Q3 2026: revenue $48.8M (+52% year over year), operating margin -159.7%. The chart follows the revenue to costs, profit and cash.
ImmunityBio: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent fda decisions
- Cabaletta Bio Nov 9, 2026
- Abeona Therapeutics Nov 9, 2026
- Abeona Therapeutics Nov 9, 2026
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.